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A B S T R A C T
Background and purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a pharmacoresistant neuro-
logical complication induced by some antitumor drugs. This study aimed to assess antiallodynic properties of
aripiprazole and ceftriaxone used alone or in combination to attenuate neuropathic pain related to CIPN caused
by oxaliplatin.
Methods: Neuropathic pain was induced in mice by a single intraperitoneal dose of oxaliplatin (10mg/kg).
Aripiprazole and ceftriaxone were used in a single- or repeated dosing protocol. Their antiallodynic activity was
assessed using von Frey and cold plate tests on the day of oxaliplatin injection and after 7 days. The influence of
aripiprazole and ceftriaxone on animals’ locomotor activity and motor coordination was also assessed.
Results: Single-dose and repeated-dose aripiprazole 10mg/kg and ceftriaxone 200mg/kg used alone and in
combination attenuated early-phase and late-phase tactile allodynia in oxaliplatin-treated mice. Repeated ad-
ministrations of ceftriaxone 200mg/kg prevented the development of late-phase tactile allodynia. Both drugs
showed no antiallodynic properties in the cold plate test. Single-dose aripiprazole 1 and 10mg/kg but not its
repeated administration significantly decreased locomotor activity of oxaliplatin-treated mice. Single-dose ar-
ipiprazole 1 and 10mg/kg, aripiprazole 1mg/kg+ ceftriaxone 50mg/kg and aripiprazole 1mg/kg+
ceftriaxone 200mg/kg impaired motor coordination in the rotarod test.
Conclusions: In mice, neither ceftriaxone nor aripiprazole attenuated cold allodynia. Ceftriaxone alone could
attenuate tactile allodynia caused by oxaliplatin without inducing motor adverse effects. Although the admin-
istration of aripiprazole reduced tactile allodynia, this effect seems to be limited considering severe motor
deficits induced by this drug.
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a non-fatal,
severe treatment-related neurological complication resulting from the
use of antitumor drugs such as vincristine, paclitaxel, platinum-based
drugs, immunomoduators, epothilones, and bortezomib. It manifests
mainly as sensory (painful) symptoms [1] and its treatment and pre-
vention are not fully addressed [2].
Oxaliplatin is a third-generation platinum-based antineoplastic
agent that alkylates DNA, thus inhibiting DNA synthesis [3]. Although
its use in advanced colorectal tumors (in combination with 5-fluor-
ouracil and folinate - FOLFOX) is well established, this therapy is often
limited by concomitant adverse effects, among which CIPN,
immunosuppressive activity and myelotoxicity are the most serious
effects that are a frequent cause of therapy discontinuation or dose
reduction [4]. CIPN induced by oxaliplatin significantly differs from
that caused by other platinum-based drugs [4], i.e., only oxaliplatin
induces CIPN that manifests in two clinically distinct forms, namely
acute and chronic. Acute neuropathy has not been reported for other
platinum-based drugs [4–6] and is usually transient lasting for hours,
often resolving within a few days [4,5]. It is observed in 86% of patients
treated with oxaliplatin and is thought to be triggered by exposure to
cold [5,6]. Cold-induced allodynia is also present in the chronic form of
CIPN caused by oxaliplatin administration, and it is noteworthy that
this chronic form of CIPN is featured by long-term peripheral sensory
damage due to neuronopathy and it may worsen for several months
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following therapy discontinuation (described as “coasting” phenom-
enon) [6]. Numerous mechanisms are implicated in both forms of CIPN.
It is thought that in the acute phase, no structural damage is present,
and oxalate released from oxaliplatin causes chelation of calcium ions,
thereby influencing ion channel functions, in particular voltage-gated
sodium channel (Nav) kinetics, whereas during the chronic phase ac-
cumulation of oxaliplatin in dorsal root ganglion cells leads to axonal
degeneration [5,6].
The difficulties in the effective treatment and prevention of CIPN
symptoms (e.g., pain) have led to the introduction of combination drug
therapy (CDT) as a method to alleviate pharmacoresistant neuropathic
pain accompanying CIPN [7,8].
This concept is supported by several recent reports showing an-
algesic efficacy of combined pregabalin and tramadol in ovarian cancer
patients on taxane-based therapy [7], combined dexmedetomidine and
ulinastatin that reduced tactile allodynia in vincristine-treated rats [9],
and the efficacy of pregabalin combined with ambroxol [10] but not
cebranopadol combined with simvastatin [11] in oxaliplatin-treated
neuropathic mice.
Apart from classical (e.g., opioidergic) drug targets that are being
investigated in the search for effective therapies for neuropathic pain in
patients treated with CIPN-inducing antitumor drugs, other neuro-
transmission systems in the CNS have also become a subject of interest
and extensive investigation for the discovery of more efficacious CIPN
therapies. However, the idea to modulate pain by using drugs that af-
fect neurotransmission systems is not novel, and this approach is con-
firmed by a successful application of antidepressant drugs as analgesic
adjuvants in various neuropathic pain types. In this respect, anti-
allodynic and antihyperalgesic effectiveness of drugs enhancing ser-
otoninergic and noradrenergic neurotransmission is very well estab-
lished [12–14]. In contrast, less is known about the role of dopamine in
pain modulation [15], although the available literature data indicate
the effectiveness of some dopaminergic modulators (e.g., duloxetine
[16,17] or bupropion [18,19]) in the attenuation of pain, including
CIPN-related pain [20–22].
The glutamatergic system also seems to be an attractive therapeutic
target in terms of pain pharmacotherapy. Glutamate is a key neuro-
transmitter that participates in the enhancement of pain signal trans-
mission and central sensitization of pain [23]. It has been reported that
down-regulation of astrocytic glutamate transporter 1 (GLT-1) is re-
sponsible for the development of neuropathic pain [24,25], and it has
been hypothesized that changes in the expression of spinal glutamate
transporters are one of the critical factors in both the induction and
maintenance of neuropathic pain [24]. Despite this widely known role
of glutamate and its transporters in pain, only ketamine, an N-methyl D-
aspartate receptor antagonist, has found a wider clinical application in
the treatment of pain.
Our previous study showed antiallodynic efficacy of NLX-112, an
agonist of serotonin 5-HT1A receptors in a mouse model of neuropathic
pain caused by oxaliplatin [12]. Also, it has been demonstrated pre-
viously that some atypical antipsychotics acting at serotonergic and
dopaminergic receptors (e.g., olanzapine, quetiapine, risperidone, zi-
prasidone and aripiprazole) attenuate several chronic pain conditions
including diabetic neuropathy, post herpetic neuralgia, headache,
musculoskeletal pain and fibromyalgia [26,27] but they have not been
investigated in neuropathic pain related to CIPN.
Hence, in the present study, we used a mouse model of CIPN in-
duced by oxaliplatin and assessed antiallodynic properties of ar-
ipiprazole – an antipsychotic drug acting as a partial agonist at dopa-
mine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin
5-HT2A receptors [28], and ceftriaxone – a blood-brain barrier-pene-
trating, third-generation cephalosporin that acts to increase GLT-1 ex-
pression and function [25,29,30]. In our study, both aripiprazole and
ceftriaxone were used alone or in combination to compare antiallodynic
properties of (1) active doses of these drugs used in monotherapy, (2)
inactive doses of these drugs used in monotherapy, and (3)
combinations of active and inactive doses of these two drugs. Test drugs
or their combinations were used in a single- or repeated (7-day) dosing
protocols, and their antiallodynic activity was assessed in the early
phase (i.e., on the day of oxaliplatin injection) and the late phase (7
days after oxaliplatin administration) of CIPN. Antinociceptive prop-
erties of aripiprazole [28] and ceftriaxone [25,31] in neuropathic pain
models have been reported recently however, none of these studies
focused on the effect of these drugs on CIPN-related neuropathic pain.
Moreover, none of these drugs were tested in a combination to alleviate
CIPN-related neuropathic pain.
The number of drugs that effectively prevent CIPN development is
very limited [21,32], and there is a paucity of reliable evidence for
drugs recommended for CIPN prevention. In this regard, further re-
search on these agents is warranted to find novel options for CIPN
prevention [1]. Hence, as a part of this present study, we additionally
aimed to establish, whether a repeated use of these drugs could prevent
the development of persistent cold and tactile allodynia in mice treated
with oxaliplatin.
2. Materials and methods
2.1. Animals and housing conditions
The experiments were performed at the Department of
Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow. The investigators involved in behavioral as-
says were blinded to the experimental groups to avoid potential bias in
data recording. Adult male Albino Swiss (CD-1) mice weighing 18–22 g
were purchased from the Animal Breeding Farm of the Jagiellonian
University Faculty of Pharmacy. Before behavioral tests, the animals
were kept in groups of 10 mice in standard plastic cages and housed
under controlled conditions (room temperature of 22 ± 2 °C, light/
dark (12:12) cycle, lights on at 8 AM, humidity 50 ± 10%, and free
access to food and water). Experimental groups consisted of 6–10 ani-
mals/dose. For behavioral tests the animals were selected randomly,
but the same animals were used throughout the two experimental ses-
sions (i.e., the acute phase and the late phase of oxaliplatin-induced
neuropathy). Between these two sessions the mice were kept in stan-
dard laboratory conditions (described above). After the assay on the last
day of experimentation (day 7), the mice were immediately euthanized
by cervical dislocation. All experiments were performed between 9 AM
and 2 PM. Experimental procedures for in vivo tests were approved by
the Local Ethics Committee of the Jagiellonian University in Krakow
(Approval No. 4/2016; 22.03.2016) and the treatment of animals was
performed in full accordance with ethical standards laid down in re-
spective Polish and EU regulations (Directive 2010/63/EU).
2.2. Chemicals
For in vivo tests, aripiprazole (Abilify 1mg/mL, Otsuka, Japan) and
ceftriaxone (Biotraxon, Polpharma S.A., Poland) were suspended in
0.9% saline (Polfa Kutno, Poland). Control animals received an ap-
propriate amount of vehicle (0.9% saline). Oxaliplatin was purchased
from Activate Scientific GmbH (Germany). To induce CIPN, oxaliplatin
was freshly prepared by dissolving in 5% glucose solution (Polfa Kutno,
Poland). The doses of aripiprazole, ceftriaxone, and oxaliplatin used in
this study were chosen on the basis of our previous research [11,33]
and available literature data [25,28,31,34].
2.3. Behavioral testing paradigm
A general description of the animal testing protocol and drug ad-
ministration schedule are shown in Fig. 1. Briefly, naïve mice involved
in the experiment were first tested for their sensitivity to mechanical
(von Frey test) and cold (cold plate test) stimuli before oxaliplatin ad-
ministration (referred to as paw withdrawal force or latencies “before
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oxaliplatin”). Then, the influence of oxaliplatin and test drugs on pain
threshold was assessed in the early phase of allodynia. At this stage of
the experiment, oxaliplatin was injected, and after 3 h, “pre-drug”
measurements were obtained again with von Frey and cold plate tests.
Aripiprazole and ceftriaxone alone or in combinations were then in-
jected intraperitoneally, and after 1 h, “post-drug” measurements were
obtained. This procedure, except for oxaliplatin injection, was repeated
after 7 days to assess the effect of oxaliplatin, aripiprazole, and cef-
triaxone on the late-phase allodynia in neuropathic mice. In the single-
dose protocol, single doses of aripiprazole and ceftriaxone were used on
day 1 and day 7 to establish their effect on the early and late phases of
allodynia. In the repeated-dose protocol, test drugs were administered
for 7 consecutive days, once daily, and the measurements of pain sen-
sitivity were collected on days 1 and 7 (Fig. 1).
2.3.1. Induction of CIPN
CIPN was induced in mice by the intraperitoneal injection of a single
dose of oxaliplatin (10mg/kg) [33]. Pain sensitivity of neuropathic
animals was measured in the cold plate test (assessment of cold allo-
dynia - for details, please see Section 2.3.2) and in the von Frey test
(assessment of tactile allodynia - for details, please see Section 2.3.3)
performed on the day of oxaliplatin administration (referred to as “day
1”) and after 7 days (“day 7”) to establish the effect of aripiprazole and
ceftriaxone, when used alone or in combination, on oxaliplatin-induced
early-phase and late-phase allodynia, respectively.
2.3.2. Influence of aripiprazole and ceftriaxone on cold allodynia – cold
plate test
The cold plate test was performed using the hot/cold plate appa-
ratus (Bioseb, France) set at 2.5 °C. In this assay, the animals were
tested first to obtain baseline latencies to pain reaction (i.e., lifting,
biting, shaking of hind paws, jumping and movement deficits) before
oxaliplatin injection (referred to as latencies “before oxaliplatin”).
Then, oxaliplatin was injected, and after 3 h, the latencies to pain re-
action were measured again (referred to as early-phase allodynia “pre-
drug latencies”). Next, test drugs were administered according to the
protocol shown in Fig. 1, and early-phase allodynia post-drug latencies
were measured. Pre-drug and post-drug latencies to pain reaction were
measured again on day 7. At this time point, oxaliplatin was not ad-
ministered. In this assay, a cut-off time of 60 s was established to avoid
potential paw tissue damage and animals not responding within 60 s
were removed from the apparatus and assigned a score of 60 s.
2.3.3. Influence of aripiprazole and ceftriaxone on tactile allodynia – von
Frey test
The test was performed on day 1 and day 7 to assess the effect of
aripiprazole and ceftriaxone used alone or in combination on tactile
allodynia caused by oxaliplatin administration during the early-phase
or late-phase sensory hypersensitivity. Mechanical hypersensitivity
(tactile allodynia) in mice was assessed using the electronic von Frey
unit (Bioseb, France) supplied with a single flexible filament applying
increasing force (from 0 to 10 g) against the plantar surface of the hind
paw of the mouse. The nocifensive paw withdrawal response auto-
matically turned off the stimulus and the mechanical pressure that
evoked the response was recorded. On the day of the experiment, the
mice were placed individually in test compartments with a wire mesh
bottom and were allowed to habituate for 1 h. After the habituation
period, to obtain baseline (pre-drug) values, each mouse was tested 3
times alternately in each hind paw, allowing at least 30 s between each
measurement. The mice were then pretreated with the test drugs or
vehicle. After 60min, the animals were tested again, and the mean post-
drug values for each mouse were obtained [35].
2.3.4. Influence on locomotor activity
The locomotor activity test was performed using activity cages
(40 cm x 40 cm x 30 cm, supplied with I.R. beam emitters) (Activity
Cage 7441, Ugo Basile, Italy) connected to a counter for the recording
of light-beam interrupts. Before the experiment, the mice were in-
traperitoneally pretreated with the test drugs or vehicle and then in-
dividually placed in the activity cages in a sound-attenuated room. The
animals' movements (i.e., the number of light-beam crossings) were
counted during the next 30min of the test. Before the experiment, the
mice were habituated to activity cages for 15min [36].
2.3.5. Influence on motor functions (rotarod test)
Before the test, the animals were trained for 3 consecutive days on the
rotarod apparatus (Rotarod apparatus, May Commat RR0711, Turkey; rod
diameter: 2 cm) that was rotated at a fixed speed of 18 rotations per
minute (rpm). In each training session, the mice were placed on the ro-
tating rod for 3min with an unlimited number of trials. The proper ex-
periment was performed 24 h after the last training session. After the
administration of the test drugs or vehicle, the mice were tested on the rod
that revolved at 6, 18, and 24 rpm. Motor impairments in mice were de-
fined as the inability to remain on the rotarod apparatus for 1min. The
results are expressed as the mean time spent on the rotarod [36].
Fig. 1. Protocol used in the present study for the assessment of interventional and preventive properties of aripiprazole and ceftriaxone alone or in combination on
tactile and cold allodynia caused by oxaliplatin administration. Tactile allodynia was measured using the von Frey test, while cold allodynia was assessed using the
cold plate test. On day 1, the effect of oxaliplatin, aripiprazole, and ceftriaxone on early-phase allodynia was evaluated. On day 7, the effect of these agents on late-
phase allodynia was assessed. Abbreviations: OXA – oxaliplatin; ARI – aripiprazole; CEF – ceftriaxone; before OXA – measurements obtained before oxaliplatin
administration; pre-drug - measurements obtained before administration of aripiprazole, ceftriaxone; post-drug - measurements obtained 1 h after administration of
aripiprazole and ceftriaxone.
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2.4. Data analysis
Data analysis was carried out using GraphPad Prism software (ver.
5.0, CA, USA). Numerical results are expressed as mean ± SEM. For
statistical analysis, one-way analysis of variance (ANOVA) followed by
Dunnett’s post hoc comparison or two-way repeated-measures ANOVA
followed by Bonferroni’s multiple comparison were used. P < 0.05 was
considered significant.
3. Results
3.1. Effect of aripiprazole and ceftriaxone on cold allodynia – cold plate test
The cold plate test performed on days 1 and 7 after oxaliplatin
administration aimed to establish (1) the effect of oxaliplatin on cold
sensitivity threshold, (2) the effect of single-dose or repeated-dose ar-
ipiprazole and ceftriaxone, each used alone or in combinations on acute
cold allodynia caused by oxaliplatin, (3) the effect of aripiprazole and
ceftriaxone on late-phase cold allodynia, and (4) the ability of these
drugs administered repeatedly after oxaliplatin injection and used alone
or in combination to prevent the development of late-phase cold allo-
dynia. The aims (2) and (3) investigated pharmacological activity of
aripiprazole and ceftriaxone as interventional drugs, whereas aim (4)
served to establish whether these drugs possess preventive properties in
CIPN-related cold allodynia.
Statistical evaluation by two-way repeated measures ANOVA did
not reveal an overall effect of treatment (F[14,131]=1.574,
p=0.0948). Time affected the results significantly (F[4,524]= 243.1,
p < 0.0001) and the interaction was also significant (F
[56,524]= 2.006, p < 0.0001).
In both early and late phases of CIPN caused by oxaliplatin, sig-
nificantly (p < 0.0001) decreased latency time to pain reaction was
observed in all groups tested compared to values obtained before ox-
aliplatin administration (Fig. 2A, B). This implies that oxaliplatin low-
ered pain threshold for cold stimulation and induced cold allodynia in
mice treated with this drug.
To assess whether aripiprazole and ceftriaxone used alone or in
combination had antiallodynic properties, post-drug latencies in drug-
treated and vehicle-treated neuropathic animals were compared.
Statistically significant differences in post-drug latencies were observed
during the early-phase cold allodynia between repeated-dose ar-
ipiprazole 10mg/kg and vehicle+ oxaliplatin-treated control mice
(p < 0.0001) (Fig. 2A). Bonferroni’s post hoc comparison also revealed
a significant (p < 0.05 vs. post-drug latency of vehicle+ oxaliplatin-
treated mice) antiallodynic effect of repeated-dose aripiprazole 1mg/kg
in the late phase. Interestingly, in the late phase, such an effect was not
observed for the dose 10mg/kg (Fig. 2B).
A detailed analysis of changes within individual groups performed
before and after treatment with aripiprazole revealed that in the early
phase, repeated-dose aripiprazole 10mg/kg increased latency time to
pain reaction (significant at p < 0.0001 vs. pre-drug latency), but this
was not observed in the late phase; similar results were obtained for
repeated-dose aripiprazole 10mg/kg+ ceftriaxone 50mg/kg in the
early phase (p < 0.01 vs. pre-drug latency), but not in the late phase of
cold allodynia (Fig. 2A, B). Taken together, in the cold plate test, ar-
ipiprazole was found to be ineffective in alleviating cold allodynia in
mice treated with oxaliplatin. Even if the dose 10mg/kg prolonged the
latency time to pain reaction in response to cold, this activity was
transient and might rather be interpreted as an effect resulting from the
reduced locomotor activity and impaired motor functions than its an-
tiallodynic effect (for details, please see Sections 3.3,3.4 and Discus-
sion).
In this test, ceftriaxone did not influence the latency time to pain
reaction and was not able to attenuate cold allodynia induced by ox-
aliplatin, either in the early or late phase of neuropathy.
3.2. Influence of aripiprazole and ceftriaxone on tactile allodynia – von
Frey test
The von Frey test performed on days 1 and 7 after oxaliplatin ad-
ministration aimed to establish (1) the effect of oxaliplatin on me-
chanical nociceptive threshold, (2) the effect of single-dose or repeated-
dose aripiprazole and ceftriaxone used alone or in combination on
early-phase tactile allodynia caused by oxaliplatin, (3) the effect of
aripiprazole and ceftriaxone on the late-phase tactile allodynia, (4) the
ability of these drugs administered repeatedly after oxaliplatin injection
and used alone or in combination to prevent the development of late-
phase tactile allodynia. Similar to the cold plate test, aims (2) and (3)
investigated pharmacological activity of aripiprazole and ceftriaxone
used as interventional drugs, whereas aim (4) served to establish
whether these drugs possess preventive properties for CIPN-related
tactile allodynia.
Statistical evaluation of the results using two-way repeated-mea-
sures ANOVA revealed an overall effect of treatment (F
[10,95]= 14.03, p < 0.0001). Time also affected the results sig-
nificantly (F[4,380]= 339.4, p < 0.0001) and the interaction was
significant (F[40,380]= 7.843, p < 0.0001).
A detailed analysis of changes within individual groups performed
Fig. 2. Effect of aripiprazole and ceftriaxone used alone or in combination on cold allodynia measured in the cold plate test in oxaliplatin-treated mice. (A): effect on
cold allodynia in the early phase of CIPN; (B): effect on cold allodynia in the late phase of CIPN. Results are shown as mean latency time to pain reaction (± SEM) for
n= 8-10. Statistical analysis: repeated-measures ANOVA followed by Bonferroni’s post hoc comparison. Significance: &: p < 0.0001 vs. latency before oxaliplatin; *:
p < 0.05 vs. post-drug latency of oxaliplatin-treated control; ****: p < 0.0001 vs. post-drug latency of oxaliplatin-treated control; #: p < 0.05 vs.pre-drug latency;
####: p < 0.0001 vs.pre-drug latency.
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before and after treatment with oxaliplatin revealed that in the early
phase of tactile allodynia (day 1) in all experimental groups, oxaliplatin
significantly lowered pain threshold for mechanical stimulation
(p < 0.0001 vs. paw withdrawal threshold before oxaliplatin injec-
tion). In contrast, on day 7, tactile allodynia was noted in all experi-
mental groups (p < 0.0001 vs. value before oxaliplatin injection), ex-
cept for the repeated-dose ceftriaxone 200mg/kg group. This indicates
that the 7-day administration of ceftriaxone 200mg/kg attenuated the
development of late-phase tactile allodynia in oxaliplatin-treated mice
(Fig. 3). In this phase, the combination of repeated-dose aripiprazole
1mg/kg and ceftriaxone 200mg/kg also elevated pain threshold of
oxaliplatin-treated mice, but in contrast to repeated-dose ceftriaxone
200mg/kg alone, this effect did not reach statistical significance.
Compared to oxaliplatin-treated control mice, a significant eleva-
tion of post-drug paw withdrawal threshold was observed in both
phases of neuropathy (Fig. 3A and B) in mice treated with single-dose
and repeated-dose aripiprazole 10mg/kg as well as in mice treated with
single-dose and repeated-dose ceftriaxone 200mg/kg (significant at
p < 0.0001). For the combined single-dose aripiprazole 1mg/kg+
ceftriaxone 50mg/kg group, the attenuation of tactile allodynia was
noted only in the early phase (p < 0.05). Combined repeated-dose
aripiprazole 1mg/kg+ ceftriaxone 50mg/kg, and single-dose and re-
peated-dose aripiprazole 1mg/kg+ ceftriaxone 200mg/kg attenuated
tactile allodynia in both early and late phases of neuropathy (significant
at p < 0.0001). For combined single-dose and repeated-dose admin-
istrations of aripiprazole 10 + ceftriaxone 50, the antiallodynic effect
was also significant in both phases of tactile allodynia (p < 0.01).
During the late-phase tactile allodynia caused by oxaliplatin
(Fig. 3B), statistically significant differences in post-drug paw with-
drawal threshold were observed between single-dose and repeated-dose
administration of aripiprazole 10mg/kg (p < 0.01); ceftriaxone
200mg/kg (p < 0.05); aripiprazole 1mg/kg+ ceftriaxone 200mg/kg
(p < 0.01); and aripiprazole 10mg/kg+ ceftriaxone 50mg/kg
(p < 0.0001).
Interestingly, during the late-phase tactile allodynia induced by
oxaliplatin, repeated administration of ceftriaxone 200mg/kg sig-
nificantly influenced pre-drug paw withdrawal threshold (p < 0.01 vs.
oxaliplatin-treated control mice). In the late phase, there were also
significant differences in pre-drug paw withdrawal threshold between
single-dose and repeated-dose ceftriaxone 200mg/kg (p < 0.001) as
well as between single-dose and repeated-dose aripiprazole 10mg/
kg+ ceftriaxone 50mg/kg (p < 0.01). Taken together, these findings
suggest that repeated administration of ceftriaxone 200mg/kg alone or
aripiprazole 10mg/kg+ ceftriaxone 50mg/kg attenuated the devel-
opment of late-phase tactile allodynia in oxaliplatin-treated mice
(Fig. 3B).
In the von Frey test, a detailed comparison of pre-drug and post-
drug values of paw withdrawal threshold within individual groups re-
vealed a significant increase in the paw withdrawal threshold in both
phases of oxaliplatin-induced tactile allodynia for single-dose and re-
peated-dose aripiprazole 10mg/kg and ceftriaxone 200mg/kg (sig-
nificant at p < 0.0001) alone, and for single-dose and repeated-dose
combination of aripiprazole 1mg/kg+ ceftriaxone 50mg/kg (sig-
nificant at p < 0.01), aripiprazole 1mg/kg+ ceftriaxone 200mg/kg
(significant at p < 0.0001), and aripiprazole 10mg/kg+ ceftriaxone
50mg/kg (significant at p < 0.001).
3.3. Influence on locomotor activity
In the locomotor activity test, an overall effect of treatment was
observed (F[16,72]= 13.55; p < 0.0001). Time also affected the re-
sults significantly (F[5,360]= 2.71; p < 0.05), but treatment x time
interaction was not significant (F[80,360]= 1.03; p=0.4117). Post
hoc analysis revealed no significant differences in animals’ locomotor
activity between non-neuropathic control mice and oxaliplatin-treated
control mice at any time point of testing. In this assay, in oxaliplatin-
treated control mice, there were no significant differences in the
number of light-beam crossings measured on day of oxaliplatin ad-
ministration and after 7 days.
In contrast, statistically significant differences in animals’ locomotor
activity were noted in mice treated with a single dose of aripiprazole
10mg/kg and aripiprazole 1mg/kg (p < 0.05 at all time points vs.
oxaliplatin-treated control on the day of oxaliplatin administration;
Fig. 4A). Interestingly, repeated administrations of aripiprazole 10mg/
kg and aripiprazole 1mg/kg also decreased locomotor activity of mice
but this effect (compared to oxaliplatin-treated control on the day of
oxaliplatin administration) did not reach statistical significance.
Single or repeated administration of ceftriaxone at doses 50 and
200mg/kg did not influence animals’ locomotor activity (Fig. 4B). In
contrast, various combinations of aripiprazole and ceftriaxone
Fig. 3. Effect of aripiprazole and ceftriaxone used alone or in combination on tactile allodynia in oxaliplatin-treated neuropathic mice as measured in the von Frey
test. (A): effect on tactile allodynia in the early phase of CIPN; (B): effect on tactile allodynia during the late phase of CIPN. Results are shown as mean paw
withdrawal threshold (± SEM) for n=8-10. Statistical analysis: repeated-measures ANOVA, followed by Bonferroni’s post hoc comparison. Significance: &:
p < 0.0001 vs. paw withdrawal threshold before oxaliplatin; *: p < 0.05 vs. post-drug paw withdrawal threshold of oxaliplatin-treated control; **: p < 0.01 vs.
post-drug paw withdrawal threshold of oxaliplatin-treated control; ****: p < 0.0001 vs. post-drug paw withdrawal threshold of oxaliplatin-treated control; ##:
p < 0.01 vs. pre-drug paw withdrawal threshold; ###: p < 0.001 vs. pre-drug paw withdrawal threshold; ####: p < 0.0001 vs. pre-drug paw withdrawal
threshold; ^^: p < 0.01 vs. pre-drug paw withdrawal threshold of oxaliplatin-treated control; +: p < 0.05 vs. single-dose post-drug paw withdrawal threshold; ++:
p < 0.01 vs. single-dose post-drug paw withdrawal threshold; ++++: p < 0.0001 vs. single-dose post-drug paw withdrawal threshold; vv: p < 0.01 vs. single-
dose pre-drug paw withdrawal threshold; vvv: p < 0.001 vs. single-dose pre-drug paw withdrawal threshold.
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significantly reduced locomotor activity of oxaliplatin-treated mice
(Fig. 4C): single-dose aripiprazole 10mg/kg co-administered with cef-
triaxone 50mg/kg (between 0–15min: p < 0.01 vs. oxaliplatin-treated
control on the day of oxaliplatin administration), repeated-dose ar-
ipiprazole 10mg/kg co-administered with ceftriaxone 50mg/kg (at all
time points except for 15–20 min: p < 0.05 vs. oxaliplatin-treated
control on the day of oxaliplatin administration), single-dose ar-
ipiprazole 1mg/kg co-administered with ceftriaxone 200mg/kg
(p < 0.05 vs. oxaliplatin-treated control on the day of oxaliplatin ad-
ministration), repeated-dose aripiprazole 1mg/kg co-administered with
ceftriaxone 200mg/kg (between 0–15min: p < 0.05 vs. oxaliplatin-
treated control on the day of oxaliplatin administration), and single-
dose and repeated-dose aripiprazole 1mg/kg combined with cef-
triaxone 50mg/kg (p < 0.05 vs. oxaliplatin-treated control on the day
of oxaliplatin administration).
3.4. Influence on motor functions (rotarod test)
In the rotarod test set at 6 rpm an overall effect of treatment was not
observed (F[15,80]= 1.276, p > 0.05). At 18 and at 24 rpm, sig-
nificant effects of treatment were noted (for 18 rpm: F[15,80]= 3.721,
p < 0.0001, and for 24 rpm: F[15,80]= 7.054, p < 0.0001). As
shown in Table 1, in the rotarod test, statistically significant differences
were observed in the selected experimental groups.
4. Discussion
Recently, we have shown that the agonism at 5-HT1A receptors at-
tenuates some pain symptoms in a mouse model of oxaliplatin-induced
neuropathic pain [12]. The main goal of the present study was to assess
whether partial agonism at dopamine D2 receptors combined with
agonism at serotonin 5-HT1A receptors or the decreased glutamate ac-
tivity resulting from the increased expression of glutamate GLT-1
transporter might attenuate tactile and cold allodynia in CIPN-related
neuropathic pain induced by oxaliplatin. For this purpose, aripiprazole
– an atypical antipsychotic drug used for the treatment of some psy-
chiatric disorders: schizophrenia and bipolar disorder, and ceftriaxone –
a third-generation cephalosporin antibiotic, each used alone or in
combination, were used, and these drugs were administered as single-
dose or repeated-dose schedules. The study was, therefore, focused on
the evaluation of these drugs’ effects used both – as “intervention” and
“prevention” protocols in CIPN-related neuropathic pain.
In mice, a single injection of oxaliplatin induced painful peripheral
neuropathy accompanied by mechanical (tactile) and cold allodynia.
These effects are widely described in the literature [37,38]. In our
study, oxaliplatin lowered pain sensitivity threshold for both thermal
and mechanical stimuli, and cold and tactile allodynia was observed as
early as 3 h after oxaliplatin injection. This effect of oxaliplatin was
persistent as it was also noted 7 days after its administration but in-
terestingly not in all experimental groups. In the von Frey test, an in-
creased pain threshold (i.e., increased pre-drug paw withdrawal in the
late phase) as compared to that of oxaliplatin-treated control mice and
that of mice receiving single-dose ceftriaxone 200mg/kg was noted in
mice that were repeatedly injected with ceftriaxone 200mg/kg. A si-
milar effect was noted in the repeated-dose aripiprazole 10mg/kg+
ceftriaxone 50mg/kg group compared to mice treated with a single-
dose combination of aripiprazole 10mg/kg+ ceftriaxone 50mg/kg.
Importantly, in the repeated-dose ceftriaxone 200mg/kg group, in the
late phase of tactile allodynia, the pre-drug paw withdrawal force was
not significantly different from that measured before oxaliplatin injec-
tion. This indicates that the 7-day administration of ceftriaxone
200mg/kg inhibited or prevented from the development of tactile al-
lodynia. This finding demonstrates a potential utility of this drug in the
prevention of development of late-phase tactile allodynia caused by
oxaliplatin. However, it should be noted here that the 7-day adminis-
tration of ceftriaxone 200mg/kg had no effect on cold allodynia in
CIPN and this seems to be the main limitation for the use of ceftriaxone
in CIPN-related cold hypersensitivity. Prevention of CIPN is regarded as
a significant and unresolved medical problem worldwide, and currently
no definite therapies for prevention are established. Therefore, it is of
key importance to search for novel preventive strategies for CIPN as
many drugs approved for the interventional use in CIPN-related pain
completely failed or showed limited preventive effect on CIPN devel-
opment [21,32]. Previously, it was demonstrated that intraperitoneally
administered ceftriaxone had both preventive and therapeutic proper-
ties in a chronic constriction injury (CCI) model of neuropathic pain in
rats. In that study, ceftriaxone prevented the development and reversed
Fig. 4. Effect of aripiprazole alone (A), ceftriaxone alone (B), and aripiprazole
and ceftriaxone used in combination (C) on animals’ locomotor activity. Results
are shown as mean number of light-beam crossings (± SEM) at selected time
points for n= 6-8. Statistical analysis: repeated-measures ANOVA followed by
Bonferroni’s post hoc comparison. Significance vs. values of oxaliplatin-treated
control measured on the day of oxaliplatin administration: * p < 0.05; **
p < 0.01; *** p < 0.001; **** p < 0.0001.
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tactile allodynia and heat hyperalgesia, and this activity was accom-
panied by an increased spinal expression of GLT-1 (EAAT2) transporter
[25]. GLT-1 is the main glutamate transporter in rats and is responsible
for the removal of 90% of extracellular glutamate in the CNS [39].
Many lines of evidence show its involvement in the development and
maintenance of acute and chronic pain [25,40]. By upregulating GLT-1
expression, ceftriaxone increased glutamate reuptake in the CNS
[30,41,42] and alleviated pain by reducing spinal astrocyte activation
and neuronal hyperexcitability [41,42]. A lowered GLT-1 expression
was found to play an important role in oxaliplatin-induced neuropathic
pain. In a study performed by Yamamoto and colleagues [43], ox-
aliplatin disrupted the extracellular glutamate homeostasis in the spinal
cord, thus resulting in neuropathic symptoms in rats. In vivo spinal
microdialysis revealed that the baseline glutamate concentration was
elevated in oxaliplatin-treated rats, and that mechanical stimulation of
the hind paw significantly increased extracellular glutamate con-
centration. In these rats, the expression of GLT-1 was decreased in the
spinal cord. Taken together, these data indicate that increasing spinal
GLT-1 expression might alleviate neuropathic pain. These findings
could be extrapolated to those obtained in our present study. In line
with this, in previous studies, downregulation of GLT-1 has been linked
with the use of taxanes [44,45]. The effect of ceftriaxone on GLT-1
expression was also confirmed in a study performed by Hajhashemi
et al. [46] who tested a 7-day administration of intraperitoneal cef-
triaxone 100–400mg/kg and noted reduced allodynia and hyperalgesia
after treatment. This beneficial effect was persistent mainly for the dose
of 200mg/kg twice daily. In the context of our present study, it should
be noted that in this previous research, one daily dose of ceftriaxone
200mg/kg only partially attenuated tactile allodynia in CCI rats and
only slightly reduced cold allodynia. This finding proved that in CCI
rats, ceftriaxone affected mechanical and to a lesser degree thermal
(cold) allodynia, suggesting that the biological functions of GLT-1 are
more associated with the regulation of mechanical nociceptive
threshold than cold nociceptive threshold [46]. This result is in line
with our present study showing that ceftriaxone 200mg/kg adminis-
tered once daily, even for 7 days, had no significant effect on cold al-
lodynia caused by oxaliplatin, but it reduced the development of tactile
allodynia. Another study also showed that the effect of ceftriaxone on
cold allodynia in CCI rats was transient, and cold allodynia was less
attenuated than mechanical allodynia [31]. At the same time, the effect
of ceftriaxone was enhanced by a co-administration with minocycline
[31]. Our previous studies also revealed that in a CIPN model in mice,
higher dose regimens of analgesic drugs are necessary for the at-
tenuation of cold allodynia than those effectively reducing tactile
allodynia [10,33]. A potential explanation for this observation is that
both cold and mechanical stimuli can activate distinct types of noci-
ceptors that are differentially sensitive to these stimulators [47,48].
The results of the present study confirmed that ceftriaxone used as
an intervention did not reduce cold allodynia in neuropathic mice, but
it effectively attenuated tactile allodynia in the von Frey test in both
phases of oxaliplatin-induced neuropathy. Similar to our finding
showing that the repeated administration of ceftriaxone 200mg/kg had
a stronger (than a single-dose ceftriaxone 200mg/kg) impact on the
reversal of tactile allodynia, in the visceral pain model, significant and
dose-dependent antinociception of ceftriaxone (25–200mg/kg per day)
was observed after the 7-day pretreatment. This effect was higher after
a 7-day pretreatment than after acute administration [34]. Anti-
allodynic properties of ceftriaxone were also enhanced by co-adminis-
tration with minocycline [31]. This effect was found to be persistent
even at low dose ceftriaxone 100mg/kg+minocycline 50mg/kg after
a 7-day treatment, but it was most enhanced in the ceftriaxone 200mg/
kg+minocycline 50mg/kg group [31]. The combinations of cef-
triaxone and nonsteroidal analgesics or levetiracetam also demon-
strated synergistic action between these drugs in rodent pain models.
These results suggest that such combination drug therapies might be
useful in the treatment of inflammation-related pain [34].
Not only GLT-1 proteins but also striatal dopamine D2 receptors and
dopaminergic pathways from the ventral tegmental area and nucleus
accumbens are thought to be involved in the regulation of pain in hu-
mans and experimental animals [49]. Positron emission tomography
technique showed that dopamine D2 receptor availability in the
striatum of healthy subjects was associated with the regulation of cold
pain threshold [50]. Furthermore, a key role of the biogenic amine
system and single nucleotide polymorphisms in serotonin and dopa-
mine transporter and receptor genes has been identified in fibromyalgia
syndrome. This resulted in altered heat, cold, and mechanical sensi-
tivity due to impairment in the ascending and descending somatosen-
sory systems and decreased CNS inhibition of peripheral nociceptive
signaling [51]. Higher extracellular dopamine levels and reduced ex-
pression of D2, but not D1, receptors in the nucleus accumbens were
noted as a possible maladaptation effect in response to chronic pain and
peripheral neuropathy [52].
Intraperitoneal aripiprazole (0.1–10mg/kg) attenuated pain re-
sponses in a mouse formalin test and diminished PGE2-induced hyper-
algesia in the paw pressure test. This effect was reversed by D2, 5-HT1A
and δ-opioid receptor antagonists, suggesting the activation of dopa-
minergic, serotonergic and δ-opioid receptors [28,53] as a possible
mechanism underlying antinociception. Therefore, it was suggested
Table 1
Effect of aripiprazole alone, ceftriaxone alone, aripiprazole and ceftriaxone used in combination, on animals’ motor coordination measured using the rotarod test.
Treatment
[mg/kg]
Time on the rotarod [s]± SEM
(6 rpm)
Time on the rotarod [s]± SEM
(18 rpm)
Time on the rotarod [s]± SEM (24 rpm)
Vehicle 54.2 ± 4.1 60.0 ± 0.0 60.0 ± 0.0
Vehicle+ oxaliplatin 60.0 ± 0.0 60.0 ± 0.0 60.0 ± 0.0
Aripiprazole 1 (single-dose) 60.0 ± 0.0 51.0 ± 3.5 19.3 ± 6.8 **
Aripiprazole 1 (repeated-dose) 51.4 ± 7.3 54.1 ± 5.9 47.8 ± 8.1
Aripiprazole 10 (single-dose) 44.8 ± 5.3 11.3 ± 7.6 *** 13.5 ± 7.1 ***
Aripiprazole 10 (repeated-dose) 60.0 ± 0.0 54.5 ± 5.0 60.0 ± 0.0
Ceftriaxone 50 (single-dose) 60.0 ± 0.0 60.0 ± 0.0 60.0 ± 0.0
Ceftriaxone 50 (repeated-dose) 57.5 ± 2.5 60.0 ± 0.0 60.0 ± 0.0
Ceftriaxone 200 (single-dose) 57.8 ± 2.3 60.0 ± 0.0 56.3 ± 3.8
Ceftriaxone 200 (repeated-dose) 60.0 ± 0.0 60.0 ± 0.0 60.0 ± 0.0
Aripiprazole 1 + Ceftriaxone 50 (single-dose) 59.3 ± 0.8 40.5 ± 8.2 28.3 ± 11.0 *
Aripiprazole 1 + Ceftriaxone 50 (repeated-dose) 60.0 ± 0.0 42.5 ± 13.5 47.0 ± 11.4
Aripiprazole 1 + Ceftriaxone 200 (single-dose) 60.0 ± 0.0 41.0 ± 12.6 22.8 ± 13.2 **
Aripiprazole 1 + Ceftriaxone 200 (repeated-dose) 60.0 ± 0.0 60.0 ± 0.0 47.8 ± 7.1
Aripiprazole 10 + Ceftriaxone 50 (single-dose) 60.0 ± 0.0 42.5 ± 13.5 34.3± 9.0
Aripiprazole 10 + Ceftriaxone 50 (repeated-dose) 59.7 ± 0.3 46.5 ± 7.1 36.1 ± 7.0
Results are shown as mean time spent on the rotarod (± SEM) revolving at 6 rpm, 18 rpm and 24 rpm for n=6-8. Statistical analysis: one-way ANOVA, followed by
Dunnett’s post hoc comparison. Significance vs. oxaliplatin-treated control on the day of oxaliplatin administration: * p < 0.05; ** p < 0.01; *** p < 0.001.
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that aripiprazole and other dopaminergic modulators should be con-
sidered as potential new treatments for certain pain types [28].
Recently, a strong link has been demonstrated between glutama-
tergic, dopaminergic and opioidergic systems in the attenuation of CCI
neuropathic pain [55]. Moreover, ceftriaxone affected dopaminergic
transmission, and in a rat model of Parkinson’s disease, it showed
neuroprotective properties [56]. It has also been shown that acute ad-
ministration of ceftriaxone attenuated allodynia by activation of do-
paminergic and opioidergic pathways [55]. Taken together, these data
indicate an important link between glutamatergic and dopaminergic
neurotransmission systems in the perception of painful stimuli and this
was the rationale for investigating the activity of ceftriaxone and ar-
ipiprazole, each used alone or in combination in this present study.
In our research, in the cold plate test, aripiprazole alone was not
generally effective, but it attenuated pain responses in the von Frey test.
This effect for single-dose administration protocols for aripiprazole
should, however, be interpreted cautiously considering the results ob-
tained in the locomotor activity and rotarod tests. Both these assays
were used for a proper interpretation of data obtained in pain tests to
avoid the possibility of false positive results [54], and they showed that
single-dose aripiprazole 10mg/kg significantly impaired motor skills of
experimental animals. Such deficits were not noted for groups treated
repeatedly with aripiprazole; this finding indicated that after repeated
dosing, mice became habituated to this negative impact of aripiprazole.
It should be clearly stated that aripiprazole-induced decreased loco-
motor acitivity is a significant limitation of the potential use of this drug
in neuropathic pain conditions, as it may worsen daily functioning of
patients. In addition, this effect may be potentiated by adverse effects of
this drug on motor functions demonstrated in the rotarod test.
In our present study we also tested combinations of ar-
ipiprazole+ ceftriaxone for their ability to attenuate allodynia caused
by oxaliplatin. Significant reduction of early-phase and late-phase tac-
tile allodynia was noted for all aripiprazole+ ceftriaxone combinations
tested. Here, these results should again be interpreted cautiously con-
sidering significantly reduced locomotor activity after the administra-
tion of all combinations tested and motor coordination deficits observed
in the rotarod test for single-dose combinations of aripiprazole 1mg/kg
and ceftriaxone 50mg/kg, or aripiprazole 1mg/kg and ceftriaxone
200mg/kg. The mechanism underlying these observed in vivo effects
remains to be fully elucidated. A potential pharmacokinetic interaction
between ceftriaxone and aripiprazole should be taken into considera-
tion. Metabolic interactions between these two drugs should rather be
excluded, considering that a large proportion of ceftriaxone is excreted
as unchanged drug [57], while aripirazole is not either cytochrome
P450 inducer or inhibitor. A pharmacokinetic drug-drug interaction at
the blood brain barrier resulting in an increased drug distribution might
be responsible for the observed adverse effects of combined aripiprazole
and ceftriaxone because ceftriaxone is a blood-brain barrier-permeating
agent and aripiprazole also acts at the CNS level.
5. Conclusions
The present study demonstrated potential utility of ceftriaxone in
the attenuation of tactile allodynia but not cold allodynia in neuro-
pathic, oxaliplatin-treated mice. In contrast, apparently beneficial re-
sults obtained for aripiprazole raise some doubts, considering that they
may be false positives resulting from the adverse effects of this drug on
the motor functions of experimental animals. Much concern is also
given to the combined use of both drugs in the view of potential adverse
effects (motor deficits and reduced locomotor activity) observed for
aripiprazole and ceftriaxone used as CDT. Also, the lack of antiallodynic
activity of ceftriaxone and aripiprazole to attenuate cold allodynia
seems to be a serious limitation for using these drugs in neuropathic
pain caused by oxaliplatin. An important finding of this present re-
search is that repeated administrations of ceftriaxone 200mg/kg at-
tenuate the development of tactile allodynia in oxaliplatin-treated mice.
It should be emphasized here that although the overuse of anti-
biotics (e.g., ceftriaxone) for non-infectious diseases might lead to mi-
crobial resistance, a reasonable application of SAR studies can provide
compounds with no antimicrobial effects but still active at GLT-1 [58].
On the basis of the present results and data from other laboratories,
such compounds would be of immense value in the prevention and
treatment of neuropathic pain of various origins. The findings of this
and previous studies propose that ceftriaxone can be included in
treatment protocols of neuropathic pain (and possibly other glutamate-
dependent diseases). In contrast, partial agonists of dopaminergic re-
ceptors, such as aripiprazole, do not seem to be useful in the treatment
of neuropathic pain induced by antitumor drugs.
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